A prefilled syringe formulation of Elyea (aflibercept injection) has been made available by Regeneron.
Eylea, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Compared with the vials, the new prefilled syringe reduces the number of preparation steps for clinicians administering Eylea. In addition to the 2mg single-dose prefilled syringe, Eylea will continue to be available in single-use vials (2mg/0.05mL).
Each prefilled syringe or vial is intended for intravitreal injection for the treatment of a single eye. If the contralateral eye requires treatment, a new sterile, prefilled syringe or vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before Eylea is administered to the other eye.
For more information visit eylea.us.
This article originally appeared on MPR